Graham Adams assesses the fallout of the Cass Review —
The press release last Thursday from the UN Special Rapporteur on violence against women and girls didn’t make the mainstream news in New Zealand but it really should have. The startling title of Reem Alsalem’s statement — “Implementation of ‘Cass report’ key to protecting girls from serious harm” — should have made news editors around the country sit up instantly and take notice.
After all, New Zealand clinicians prescribe puberty blockers to gender-distressed young people at more than 10 times the rate of Britain — as University of Otago emeritus professor Charlotte Paul told Sean Plunket recently (and North & South magazine last November). And most of the hundreds of young people in New Zealand aged 12 to 17 who are taking puberty blockers are girls.
You might imagine that such enthusiastic dispensing would make the findings by English paediatric consultant Dr Hilary Cass highly newsworthy here but our legacy media doesn’t seem to be particularly interested. Perhaps that shouldn’t be surprising given they have for years vilified critics of the “affirmative” treatment of gender-distressed young people as transphobes while insisting the “science is settled”. Unfortunately for them, Cass has decisively unsettled that belief.
In her report — commissioned by England’s National Health Service (NHS) and published on April 10 — she advised that such powerful medical treatments need to be supported by strong evidence, and so far such a firm underpinning is lacking: “The reality is that we have no good evidence on the long-term outcomes of interventions to manage gender-related distress.” The existing evidence for prescribing gender medicine, she said, is built on “shaky foundations”.
Continue reading “NZ’s trans lobby is fighting a rearguard action” →